Literature DB >> 32293834

Antiviral treatment of COVID-19

Serap Şimşek Yavuz1, Serhat Ünal2.   

Abstract

Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%–10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections. This work is licensed under a Creative Commons Attribution 4.0 International License.

Entities:  

Keywords:  Covid-19; Sars-CoV-2; antiviral

Year:  2020        PMID: 32293834     DOI: 10.3906/sag-2004-145

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  79 in total

Review 1.  Controlling the Burden of COVID-19 by Manipulating Host Metabolism.

Authors:  Logan Miller; Engin Berber; Deepak Sumbria; Barry T Rouse
Journal:  Viral Immunol       Date:  2021-12-13       Impact factor: 2.257

2.  Trend Dynamics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission in 16 Cities of Hubei Province, China.

Authors:  Muhammad Fawad; Sumaira Mubarik; Saima Shakil Malik; Yangyang Hao; Chuanhua Yu; Jingli Ren
Journal:  Clin Epidemiol       Date:  2020-07-02       Impact factor: 4.790

3.  Caregivers' intentions to COVID-19 vaccination for their children in China: a cross-sectional survey.

Authors:  Huangyufei Feng; He Zhu; Haijun Zhang; Lingsheng Cao; Li Li; Jiaohao Wang; Yingzhe Huang; Xiaozhen Lai; Yun Lyu; Rize Jing; Jia Guo; Zundong Yin; Hai Fang
Journal:  Hum Vaccin Immunother       Date:  2021-11-10       Impact factor: 3.452

4.  Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs.

Authors:  Sk Md Nayeem; E Mohammed Sohail; N V Srihari; P Indira; M Srinivasa Reddy
Journal:  J Biomol Struct Dyn       Date:  2021-05-14

5.  Prevalence and cross states comparison of case fatality rate and recovery rate of COVID 19/SARS-COV-2 in India.

Authors:  Ajaz Ahmed Z Ansari; Hardik D Desai; Kamal Sharma; Dhigishaba M Jadeja; Rahul Patel; Yesha Patel; Harshil M Desai
Journal:  J Family Med Prim Care       Date:  2021-01-30

6.  Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID-19 using favipiravir.

Authors:  Muhammet Ali Oruç; Hatice Öz; Onur Öztürk
Journal:  Int J Clin Pract       Date:  2021-03-29       Impact factor: 3.149

7.  Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU

Authors:  Nursel Çalık Başaran; Oğuz Abdullah Uyaroğlu; Gülçin Telli Dizman; Lale Özışık; Taha Koray Şahin; Zahit Taş; Ahmet Çağkan İnkaya; Sevilay Karahan; Şehnaz Alp; Alpaslan Alp; Gökhan Metan; Pınar Zarakol; Gülay Sain Güven; Şerife Gül Öz; Arzu Topeli; Ömrüm Uzun; Murat Akova; Serhat Ünal
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

8.  Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.

Authors:  Seyed MohammadReza Hashemian; Batoul Khoundabi; Ali Akbar Velayati
Journal:  Int Immunopharmacol       Date:  2021-05-28       Impact factor: 4.932

Review 9.  The Relationship Between Vitamin D and Infections Including COVID-19: Any Hopes?

Authors:  Rbab Taha; Shahd Abureesh; Shuruq Alghamdi; Rola Y Hassan; Mohamed M Cheikh; Rania A Bagabir; Hani Almoallim; Altaf Abdulkhaliq
Journal:  Int J Gen Med       Date:  2021-07-24

10.  Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study.

Authors:  Xianlong Zhou; Haifeng Hou; Luyu Yang; Guoyong Ding; Tao Wei; Cancan Li; Yuanyuan Heng; Ruining Liu; Min Ma; Zhuanzhuan Hu; Lei Huang; Xizhu Xu; Quan Hu; Yan Zhao; Weijia Xing; Zhigang Zhao
Journal:  J Glob Health       Date:  2021-07-17       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.